戻る Agenda
Oral Poster Session 2 - Clinical Development & Pharmacovigilance Content Hub
Learning Objective : To present information gathered over the years 2017-2019 from current and potential customers including large innovative pharmaceutical companies, orphan drug, and generics companies, on their views of outsourcing pharmacovigilance functions, in particular the EU QPPV role, and the impact of Brexit.
Speaker(s)
Considerations for outsourcing EU QPPV services taking into account the impact of Brexit
Kosta Cvijovic, PHD, MPHARM
Syneos Health, Austria
EU QPPV
Internal Safety Advisory Groups (ISAG): A Win-Win for Effective Decision-Making in Biopharmaceutical Companies
Eric B Cohen, MD
AbbVie, United States
Senior Medical Director
CAST analysis of UK pregnancies reported after isotretinoin administration
Brian Edwards, DrMed
International Society of Pharmacovigilance, United Kingdom
Director